Contraindicated (one)bortezomib will enhance the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors could maximize mavacamten systemic exposure, resulting in heart failure as a result of systolic dysfunction. Drug Formulary info is intended for use by healthcare gurus. It's not at https://tanshinone-i47677.bligblogging.com/27274366/the-smart-trick-of-dup-747-that-nobody-is-discussing